Novo Nordisk

Foreign Filer Report • Feb 6, 2025

6-K 1 f6k_020625.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____

FORM 6-K

____

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

February 6, 2025

____

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

____

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Field: Page; Sequence: 1; Options: NewSection

Field: /Page

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 3

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Liselotte
Sofie Hyveled | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Member
of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 1,407 shares |
| d) | Aggregated information · Aggregated volume · Price | 1,407 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 4

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 98,702 shares |
| d) | Aggregated information · Aggregated volume · Price | 98,702 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 5

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 618.10 DKK | 32 shares |
| d) | Aggregated information · Aggregated volume · Price | 32 shares 19,779 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | AQUIS
EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 6

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 619.48 DKK | 1,104 shares |
| d) | Aggregated information · Aggregated volume · Price | 1,104 shares 683,905 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | AQUIS
EXCHANGE EUROPE | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 7

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 617.56 DKK | 978 shares |
| d) | Aggregated information · Aggregated volume · Price | 978 shares 603,976 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | CBOE
EUROPE - DXE PERIODIC (NL) | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 8

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 621.01 DKK | 42 shares |
| d) | Aggregated information · Aggregated volume · Price | 42 shares 26,083 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | CBOE
EUROPE - DXE DARK ORDER BOOK (NL) | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 9

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 618.17 DKK | 8,331 shares |
| d) | Aggregated information · Aggregated volume · Price | 8,331 shares 5,149,984 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | CBOE
EUROPE - DXE ORDER BOOKS (NL) | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 10

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 618.14 DKK | 1,577 shares |
| d) | Aggregated information · Aggregated volume · Price | 1,577 shares 974,805 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | TURQUOISE EUROPE | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 11

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Lars
Fruergaard Jørgensen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | President
and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | 618.88 DKK | 22,936 shares |
| d) | Aggregated information · Aggregated volume · Price | 22,936 shares 14,194,575 DKK | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | NASDAQ
COPENHAGEN A/S | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 12

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Maziar
Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 36,956 shares |
| d) | Aggregated information · Aggregated volume · Price | 36,956 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 13

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Maziar
Mike Doustdar | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 614.55 | 1,852 shares |
| d) | Aggregated information · Aggregated volume · Price | 1,852 shares DKK 1,138,154 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Nasdaq
Copenhagen | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 14

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Ludovic Helfgott | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 27,765 shares |
| d) | Aggregated information · Aggregated volume · Price | 27,765 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 15

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Ludovic Helfgott | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 614.55 | 8,990 shares |
| d) | Aggregated information · Aggregated volume · Price | 8,990 shares DKK 5,524,840 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Nasdaq
Copenhagen | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 16

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Ludovic Helfgott | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 617.00 | 12,000 shares |
| d) | Aggregated information · Aggregated volume · Price | 12,000 shares DKK 7,404,000 | |
| e) | Date
of the transaction | 2025-02- 06 | |
| f) | Place
of the transaction | Nasdaq
Copenhagen | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 17

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Karsten
Munk Knudsen | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 30,728 shares |
| d) | Aggregated information · Aggregated volume · Price | 30,728 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 18

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Martin
Holst Lange | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 30,728 shares |
| d) | Aggregated information · Aggregated volume · Price | 30,728 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 19

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Tania Sabroe | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 10,561 shares |
| d) | Aggregated information · Aggregated volume · Price | 10,561 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 20

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Marcus Schindler | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 30,728 shares |
| d) | Aggregated information · Aggregated volume · Price | 30,728 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 21

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Camilla Sylvest | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 30,728 shares |
| d) | Aggregated information · Aggregated volume · Price | 30,728 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 22

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Camilla Sylvest | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Sale
of shares | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 615.00 | 15,364 shares |
| d) | Aggregated information · Aggregated volume · Price | 15.364 shares DKK 9,448,860 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Nasdaq
Copenhagen | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 23

Field: /Page

| 1 — a) | Details
of the person discharging managerial responsibilities/person closely associated — Name
of the Board member/Executive/Associated Person | Henrik
Ehlers Wulff | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive
Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details
of the issuer | | |
| a) | Name | Novo
Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, type
of instrument, | Shares | |
| | Identification
code | Novo
Nordisk B DK0062498333 | |
| b) | Nature
of the transaction | Other
transaction (transfer of shares in accordance
with Long Term Incentive programme) | |
| c) | Price(s)
and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 32,448 shares |
| d) | Aggregated information · Aggregated volume · Price | 32,448 shares DKK 0.00 | |
| e) | Date
of the transaction | 2025-02- 05 | |
| f) | Place
of the transaction | Outside
a trading venue | |

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 24

Field: /Page

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg
Rode +45 3075 5956 jrde@novonordisk.com	David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com	Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com	Frederik Taylor
Pitter +1 609 613 0568 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations
Company announcement No 8 / 2025

Field: Page; Sequence: 25

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 6, 2025 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer

Field: Rule-Page

Field: /Rule-Page